Skip to main content
Premium Trial:

Request an Annual Quote

Sirius Collaborates with Parisian Hospitals

NEW YORK (GenomeWeb News) – Sirius Genomics will work with the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic markers for severe sepsis under a collaborative agreement, the company said today.

Sirius will work with the hospital system's Clinical Research and Development Department in a program aimed at developing a pharmacogenomic diagnostic to assess the responsiveness of severe sepsis patients to recombinant human activated Protein C, which is sold by Eli Lilly under the trade name Xigris.

"Access to AP-HP's severe sepsis patients will be critical in the validation of Sirius' sepsis biomarkers," Sirius President and CEO Brad Popovich said in a statement.

AP-HP is a public health system that includes 37 hospitals and undertakes an array of activities beyond healthcare, including research, health education, home nursing, teaching, and others.

Financial terms of the agreement were not disclosed.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.